Asset Details
Do you wish to reserve the book?
Geniposide ameliorates TNBS-induced experimental colitis in rats via reducing inflammatory cytokine release and restoring impaired intestinal barrier function
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Geniposide ameliorates TNBS-induced experimental colitis in rats via reducing inflammatory cytokine release and restoring impaired intestinal barrier function
Do you wish to request the book?
Geniposide ameliorates TNBS-induced experimental colitis in rats via reducing inflammatory cytokine release and restoring impaired intestinal barrier function
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Geniposide ameliorates TNBS-induced experimental colitis in rats via reducing inflammatory cytokine release and restoring impaired intestinal barrier function
2017
Overview
Geniposide is an iridoid glycosides purified from the fruit of Gardenia jasminoides Ellis, which is known to have antiinflammatory, anti- oxidative and anti-tumor activities. The present study aimed to investigate the effects of geniposide on experimental rat colitis and to reveal the related mechanisms, Experimental rat colitis was induced by rectal administration of a TNBS solution. The rats were treated with geniposide （25, 50 mg.kg-1.d-1, ig） or with sulfasalazine （SASP, 100 mg.kg-1.d-1, ig） as positive control for 14 consecutive days. A Caco-2 cell monolayer exposed to lipopotysaccharides （LPS） was used as an epithelial barrier dysfunction model. Transepithelial electrical resistance （TER） was measured to evaluate intestinal barrier function. In rats with TNBS-induced colitis, administration of geniposide or SASP significantly increased the TNBS-decreased body weight and ameliorated TNBS-induced experimental colitis and related symptoms. Geniposide or SASP suppressed inflammatory cytokine （TNF-α, IL-1β, and IL-6） release and neutrophil infiltration （myeloperoxidase activity） in the colon. In Caco-2 ceils, geniposide （25-100 pg/mL） ameliorated LPS-induced endothelial barrier dysfunction via dose-dependently increasing transepithelial electrical resistance （TER）. The results from both in vivo and in vitro studies revealed that geniposide down-regulated NF-KB, COX-2, iNOS and MLCK protein expression, up-regulated the expression of tight junction proteins （occludin and ZO-1）, and facilitated AMPK phosphorylation. Both AMPK siRNA transfection and AMPK overexpression abrogated the geniposide-reduced MLCK protein expression, suggesting that geniposide ameliorated barrier dysfunction via AMPK- mediated inhibition of the MLCK pathway. In conclusion, geniposide ameliorated TNBS-induced experimental rat colitis by both reducing inflammation and modulating the disrupted epithelial barrier function via activating the AMPK signaling pathway.
Publisher
Nature Publishing Group UK,Nature Publishing Group
Subject
/ Anti-Inflammatory Agents, Non-Steroidal - administration & dosage
/ Anti-Inflammatory Agents, Non-Steroidal - therapeutic use
/ Biomedical and Life Sciences
/ Colitis, Ulcerative - chemically induced
/ Colitis, Ulcerative - drug therapy
/ Colitis, Ulcerative - metabolism
/ Humans
/ Iridoids - administration & dosage
/ Male
/ Neutrophil Infiltration - drug effects
/ Original
/ Sulfasalazine - therapeutic use
/ Trinitrobenzenesulfonic Acid
/ Vaccine
